MCID: IDP024
MIFTS: 49

Idiopathic Inflammatory Myopathy

Categories: Rare diseases, Genetic diseases

Aliases & Classifications for Idiopathic Inflammatory Myopathy

MalaCards integrated aliases for Idiopathic Inflammatory Myopathy:

Name: Idiopathic Inflammatory Myopathy 53 25
Idiopathic Inflammatory Myopathies 25 73
Idiopathic Inflammatory Myositis 53 25
Myositis 53 73
Idiopathic Inflammatory Myopathy, Familial 53
Myopathies Idiopathic Inflammatory 55
Inflammatory Myopathy, Idiopathic 25
Iim 53
Imm 53

Classifications:



External Ids:

UMLS 73 C0751356

Summaries for Idiopathic Inflammatory Myopathy

NIH Rare Diseases : 53 Idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). Although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. Signs and symptoms of the condition include muscle weakness, joint pain and fatigue. There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis, which are each associated with unique features. As the name suggests, the cause of the condition is currently unknown (idiopathic). However, researchers suspect that it may occur due to a combination of genetic and environmental factors. Treatment is supportive and based on the signs and symptoms present in each person.

MalaCards based summary : Idiopathic Inflammatory Myopathy, also known as idiopathic inflammatory myopathies, is related to myositis and rheumatoid arthritis, and has symptoms including back pain, muscle cramp and muscle rigidity. An important gene associated with Idiopathic Inflammatory Myopathy is TRIM21 (Tripartite Motif Containing 21), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Simvastatin and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, lung and tongue, and related phenotype is Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers.

Genetics Home Reference : 25 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age.

Wikipedia : 76 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Related Diseases for Idiopathic Inflammatory Myopathy

Diseases related to Idiopathic Inflammatory Myopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 myositis 30.2 HLA-DRB1 TRIM21
2 rheumatoid arthritis 27.6 HLA-B HLA-DQA1 HLA-DRB1 IL1A
3 congenital disorder of glycosylation, type iim 12.4
4 childhood type dermatomyositis 11.3
5 necrotizing autoimmune myopathy 11.3
6 slc35a2-cdg 11.3
7 myopathy 10.8
8 postherpetic neuralgia 10.3 HLA-B HLA-DRB1
9 microscopic polyangiitis 10.3 HLA-B HLA-DRB1
10 pityriasis rosea 10.2 HLA-B HLA-DRB1
11 acute disseminated encephalomyelitis 10.2 HLA-B HLA-DRB1
12 nontuberculous mycobacterial lung disease 10.2 HLA-B HLA-DRB1
13 histoplasmosis 10.2 HLA-B HLA-DRB1
14 alveolar echinococcosis 10.2 HLA-B HLA-DRB1
15 pure red-cell aplasia 10.2 HLA-B HLA-DRB1
16 panuveitis 10.2 HLA-B HLA-DRB1
17 dermatomyositis 10.2
18 interstitial lung disease 10.2
19 lung disease 10.2
20 geographic tongue 10.2 HLA-B HLA-DRB1
21 periodontitis, aggressive, 1 10.2 HLA-B IL1A
22 idiopathic neutropenia 10.2 HLA-DRB1 IL1A
23 paraneoplastic pemphigus 10.1 HLA-B HLA-DRB1
24 echinococcosis 10.1 HLA-B HLA-DRB1
25 rubella 10.1 HLA-B HLA-DRB1
26 sclerosing cholangitis 10.1 HLA-B HLA-DRB1
27 takayasu arteritis 10.1 HLA-B HLA-DRB1
28 bone inflammation disease 10.1 HLA-DRB1 IL1A
29 polymyositis 10.0
30 cholangitis 10.0 HLA-B HLA-DRB1
31 antisynthetase syndrome 10.0
32 endotheliitis 10.0
33 hypersensitivity reaction disease 9.9 HLA-DRB1 TRIM21
34 focal epithelial hyperplasia 9.9 HLA-DQA1 HLA-DRB1
35 recurrent respiratory papillomatosis 9.9 HLA-DQA1 HLA-DRB1
36 eosinophilia-myalgia syndrome 9.9 HLA-DQA1 HLA-DRB1
37 uveitis 9.9 HLA-B IL1A
38 sympathetic ophthalmia 9.9 HLA-DQA1 HLA-DRB1
39 inclusion body myositis 9.9
40 arthritis 9.9
41 oligoarticular juvenile idiopathic arthritis 9.8 HLA-DQA1 HLA-DRB1
42 rheumatic heart disease 9.8 HLA-DQA1 HLA-DRB1
43 myocardial infarction 9.7
44 polyglucosan body myopathy 1 with or without immunodeficiency 9.7
45 acute myocardial infarction 9.7
46 osteoarthritis 9.7
47 extrapulmonary tuberculosis 9.7
48 esophagitis 9.7
49 dyskeratosis congenita 9.7
50 myocarditis 9.7

Graphical network of the top 20 diseases related to Idiopathic Inflammatory Myopathy:



Diseases related to Idiopathic Inflammatory Myopathy

Symptoms & Phenotypes for Idiopathic Inflammatory Myopathy

UMLS symptoms related to Idiopathic Inflammatory Myopathy:


back pain, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, myalgia

GenomeRNAi Phenotypes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased influenza A H1N1 (A/Hamburg/04/2009) virus numbers GR00195-A-3 8.62 IL1A TRIM21

Drugs & Therapeutics for Idiopathic Inflammatory Myopathy

Drugs for Idiopathic Inflammatory Myopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 164)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
2
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
5
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
6
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
7 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 3
8
Tenofovir Phase 4 147127-20-6 464205
9 beta-endorphin Phase 4,Phase 2
10 Rosuvastatin Calcium Phase 4,Not Applicable 147098-20-2
11 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
12 Reverse Transcriptase Inhibitors Phase 4,Not Applicable
13 Adrenocorticotropic Hormone Phase 4,Phase 2
14 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
15 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
17 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Vaccines Phase 4,Phase 3
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
22 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Not Applicable
23 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Not Applicable
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-HIV Agents Phase 4,Not Applicable
27 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Not Applicable
28 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29 Melanocyte-Stimulating Hormones Phase 4,Phase 2
30 Anti-Retroviral Agents Phase 4,Not Applicable
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
32 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
33 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Calcium, Dietary Phase 4,Phase 2,Early Phase 1,Not Applicable
36 Atorvastatin Calcium Phase 4,Not Applicable 134523-03-8
37
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
38
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
39
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
40
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
41
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
42
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
43
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
44
Zanamivir Approved, Investigational Phase 3 139110-80-8 60855
45
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
46
Infliximab Approved Phase 2, Phase 3 170277-31-3
47
Mesna Approved, Investigational Phase 2, Phase 3 3375-50-6 598
48
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
49
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
50
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 185243-69-0

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
4 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
5 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
6 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
7 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
8 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
9 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
10 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
11 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
13 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
14 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
15 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
16 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
17 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
18 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
19 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
20 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
21 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
22 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
23 A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection Completed NCT01527110 Phase 3 Intravenous (IV) zanamivir
24 A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children Completed NCT01218308 Phase 3
25 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
26 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
27 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
28 Belimumab in Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
29 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Recruiting NCT02728752 Phase 3 Octagam 10%
30 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Recruiting NCT03312634 Phase 3 Palovarotene
31 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
32 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Recruiting NCT03381196 Phase 3 Pimodivir 600 mg;Placebo
33 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Recruiting NCT03376321 Phase 3 Pimodivir 600 mg;Placebo
34 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Active, not recruiting NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
35 L-Citrulline in Patients With Post-Polio Syndrome Active, not recruiting NCT02801071 Phase 3 15g L-citrulline daily p.o.;Placebo
36 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Not yet recruiting NCT03486873 Phase 3 Standard of Care (SOC)
37 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
38 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
39 Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
40 Alemtuzumab to Treat Sporadic Inclusion Body Myositis Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
41 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
42 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
43 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
44 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
45 An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Completed NCT02190747 Phase 2 Palovarotene;Placebo
46 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
47 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
48 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
49 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
50 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil

Search NIH Clinical Center for Idiopathic Inflammatory Myopathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Idiopathic Inflammatory Myopathy

Anatomical Context for Idiopathic Inflammatory Myopathy

MalaCards organs/tissues related to Idiopathic Inflammatory Myopathy:

41
Skeletal Muscle, Lung, Tongue, Bone, Prostate, Eye, Skin

Publications for Idiopathic Inflammatory Myopathy

Articles related to Idiopathic Inflammatory Myopathy:

(show top 50) (show all 153)
# Title Authors Year
1
Venous thromboembolic events in idiopathic inflammatory myopathy - occurrence and relation to disease onset. ( 29579357 )
2018
2
The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. ( 29541951 )
2018
3
Correction: <i>Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study</i>. ( 29650643 )
2018
4
Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. ( 29429407 )
2018
5
Effect of Adalimumab on Refractory Arthritis in Juvenile Idiopathic Inflammatory Myopathy with Anti-MDA5 Autoantibody. ( 29552370 )
2018
6
Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. ( 29513937 )
2018
7
Early detection of myocardial involvement by T<sub>1</sub>mapping of cardiac MRI in idiopathic inflammatory myopathy. ( 29328539 )
2018
8
Is it cardiac involvement mimicking acute myocardial infarction in idiopathic inflammatory myopathy? ( 28672937 )
2017
9
Ro52/TRIM21-deficient expression and function in different subsets of peripheral blood mononuclear cells is associated with a proinflammatory cytokine response in patients with idiopathic inflammatory myopathies. ( 27936488 )
2017
10
Idiopathic inflammatory myopathy and the risk of venous thromboembolism: a meta-analysis. ( 28493173 )
2017
11
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy. ( 29222707 )
2017
12
The PTPN22 gene is associated with idiopathic inflammatory myopathy. ( 27312665 )
2017
13
Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies. ( 28660228 )
2017
14
Multiple values of (18)F-FDG PET/CT in idiopathic inflammatory myopathy. ( 28831580 )
2017
15
AIIMDs: An Integrated Framework of Automatic Idiopathic Inflammatory Myopathy Diagnosis for Muscle. ( 28422672 )
2017
16
Investigating Idiopathic Inflammatory Myopathy; Initial Cross Speciality Experience with Use of the Extended Myositis Antibody Panel. ( 28567235 )
2017
17
Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. ( 28814428 )
2017
18
Idiopathic Inflammatory Myopathies: Clinical Approach and Management. ( 27242652 )
2016
19
Autoantibodies in adult patients with idiopathic inflammatory myopathies in Buenos Aires. ( 27295700 )
2016
20
Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. ( 27388770 )
2016
21
Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review. ( 27504827 )
2016
22
Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies. ( 27173897 )
2016
23
Long-term follow-up of patients with idiopathic inflammatory myopathy at Waitemata District Health Board. ( 26914299 )
2016
24
Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies. ( 27642533 )
2016
25
High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. ( 27412148 )
2016
26
Diagnosis and classification of idiopathic inflammatory myopathies. ( 27320359 )
2016
27
Seasonality of birth patterns in an Australian cohort of patients with biopsy-confirmed idiopathic inflammatory myopathy. ( 27170240 )
2016
28
Thigh magnetic resonance imaging for the evaluation of disease activity in patients with idiopathic inflammatory myopathies followed in a single center. ( 27279002 )
2016
29
Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. ( 27894310 )
2016
30
The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. ( 27522114 )
2016
31
213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015. ( 27312023 )
2016
32
High resolution manometry in patients with idiopathic inflammatory myopathy: Elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset. ( 27935079 )
2016
33
PET/CT scan revealing active idiopathic inflammatory myopathy with normal serum sarcoplasmic enzymes levels. ( 26968020 )
2016
34
Investigation into the cause of mortality in 49 cases of idiopathic inflammatory myopathy: A single center study. ( 26998007 )
2016
35
The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. ( 27028907 )
2016
36
Case Report: Elevated CPK, an indicator of idiopathic inflammatory myopathy? ( 27540467 )
2016
37
Necrotizing Autoimmune Myopathy: A Unique Subset of Idiopathic Inflammatory Myopathy. ( 27660937 )
2016
38
Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy. ( 27878344 )
2016
39
Muscle Metabolic Responses During Dynamic In-Magnet Exercise Testing: A Pilot Study in Children with an Idiopathic Inflammatory Myopathy. ( 26259546 )
2015
40
Discovery of new biomarkers of idiopathic inflammatory myopathy. ( 25681646 )
2015
41
Vitamin D receptor gene polymorphisms and haplotypes in Hungarian patients with idiopathic inflammatory myopathy. ( 25649962 )
2015
42
HMGB1 expression and muscle regeneration in idiopathic inflammatory myopathies and degenerative joint diseases. ( 25761565 )
2015
43
Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy. ( 25490616 )
2015
44
Infantile-onset LMNA-associated Muscular Dystrophy Mimicking Juvenile Idiopathic Inflammatory Myopathy. ( 26034236 )
2015
45
Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. ( 26337070 )
2015
46
Extrapulmonary Tuberculosis Infection in Mexican Patients With Idiopathic Inflammatory Myopathies. ( 26308355 )
2015
47
Early diagnosis of cardiac involvement in idiopathic inflammatory myopathy by cardiac magnetic resonance tomography. ( 25673126 )
2015
48
Increased osteopontin in muscle and serum from patients with idiopathic inflammatory myopathies. ( 25936410 )
2015
49
Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. ( 26922197 )
2015
50
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. ( 26424665 )
2015

Variations for Idiopathic Inflammatory Myopathy

Expression for Idiopathic Inflammatory Myopathy

Search GEO for disease gene expression data for Idiopathic Inflammatory Myopathy.

Pathways for Idiopathic Inflammatory Myopathy

Pathways related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.58 HLA-B HLA-DQA1 HLA-DRB1 IL1A TRIM21
2
Show member pathways
13.04 HLA-B HLA-DQA1 HLA-DRB1 TRIM21
3
Show member pathways
12.58 HLA-B HLA-DQA1 HLA-DRB1
4
Show member pathways
12.46 HLA-B HLA-DQA1 HLA-DRB1 IL1A TRIM21
5
Show member pathways
12.45 HLA-B HLA-DQA1 HLA-DRB1 IL1A
6
Show member pathways
12.31 HLA-B HLA-DQA1 HLA-DRB1 IL1A
7
Show member pathways
12.12 HLA-DQA1 HLA-DRB1 IL1A
8 12.09 HLA-B HLA-DQA1 HLA-DRB1
9 11.97 HLA-B HLA-DQA1 HLA-DRB1
10
Show member pathways
11.93 HLA-DQA1 HLA-DRB1 IL1A
11 11.89 HLA-DQA1 HLA-DRB1 IL1A
12
Show member pathways
11.84 HLA-DQA1 HLA-DRB1
13 11.79 HLA-B HLA-DQA1 HLA-DRB1
14 11.7 HLA-B HLA-DQA1 HLA-DRB1
15
Show member pathways
11.64 HLA-DQA1 HLA-DRB1
16 11.6 HLA-DQA1 HLA-DRB1
17 11.59 HLA-DQA1 HLA-DRB1
18 11.42 HLA-DQA1 HLA-DRB1
19 11.42 HLA-DQA1 HLA-DRB1 IL1A
20
Show member pathways
11.42 HLA-B HLA-DQA1 HLA-DRB1 TRIM21
21 11.3 HLA-DQA1 HLA-DRB1
22 11.29 HLA-DQA1 HLA-DRB1 IL1A
23 11.01 HLA-DRB1 IL1A

GO Terms for Idiopathic Inflammatory Myopathy

Cellular components related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.61 HLA-B HLA-DQA1 HLA-DRB1
2 trans-Golgi network membrane GO:0032588 9.4 HLA-DQA1 HLA-DRB1
3 endocytic vesicle membrane GO:0030666 9.37 HLA-DQA1 HLA-DRB1
4 transport vesicle membrane GO:0030658 9.32 HLA-DQA1 HLA-DRB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.26 HLA-DQA1 HLA-DRB1
6 MHC class II protein complex GO:0042613 9.16 HLA-DQA1 HLA-DRB1
7 ER to Golgi transport vesicle membrane GO:0012507 9.13 HLA-B HLA-DQA1 HLA-DRB1
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-B HLA-DQA1 HLA-DRB1

Biological processes related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.54 HLA-B HLA-DQA1 HLA-DRB1
2 immune response GO:0006955 9.46 HLA-B HLA-DQA1 HLA-DRB1 IL1A
3 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.4 HLA-DQA1 HLA-DRB1
4 T cell costimulation GO:0031295 9.32 HLA-DQA1 HLA-DRB1
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DQA1 HLA-DRB1
6 antigen processing and presentation GO:0019882 9.13 HLA-B HLA-DQA1 HLA-DRB1
7 interferon-gamma-mediated signaling pathway GO:0060333 8.92 HLA-B HLA-DQA1 HLA-DRB1 TRIM21

Molecular functions related to Idiopathic Inflammatory Myopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DQA1 HLA-DRB1
2 peptide antigen binding GO:0042605 8.8 HLA-B HLA-DQA1 HLA-DRB1

Sources for Idiopathic Inflammatory Myopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....